Reducing neuroinflammation may be new pathway for Alzheimer’s therapy

Table of Contents

Findings reveal how chronic inhibition of a key immune pathway enhances microglial function and reduces disease progression.

Alzheimer’s disease is characterized by the accumulation of amyloid-β plaques and tau tangles in the brain; however, emerging evidence suggests that neuroinflammation plays a central role in disease progression.

Published in Immunity, a recent study by researchers at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn provides new insights into how targeting the NLRP3 inflammasome – a key regulator of the immune response – could modulate metabolic and mitochondrial function in microglia, enhancing their ability to clear amyloid-β and potentially slow the progression of Alzheimer’s disease [1].

Longevity.Technology: Understanding the role of neuroinflammation is crucial for developing effective therapeutics for Alzheimer’s disease. Neuroinflammation is not merely a secondary consequence of amyloid-β accumulation – rather, it appears to be a driver of disease pathology. Research suggests that neuroinflammation occurs early in Alzheimer’s progression – possibly preceding the formation of plaques – offering a promising target for intervention. Modulating microglial activity and inflammatory pathways could lead to therapies that address multiple aspects of Alzheimer’s simultaneously, particularly given the limited success of current treatments focused solely on amyloid-β or tau. The prospect of targeting neuroinflammation for prevention, rather than treatment alone, may also open new avenues for slowing cognitive decline before irreversible damage occurs.

Chronic inhibition of NLRP3 alters microglial metabolism

The study builds on previous findings that activation of the NLRP3 inflammasome exacerbates Alzheimer’s pathology by promoting the release of inflammatory cytokines, such as interleukin-1β (IL-1β), and enhancing amyloid-β aggregation. Using a combination of genetic and pharmacological approaches, the researchers demonstrated that blocking NLRP3 activity shifts microglial metabolism towards a more oxidative, energy-efficient state, increasing their ability to engulf and degrade amyloid-β.

Microglia – the brain’s primary immune cells – exhibit distinct functional states depending on their metabolic profile. In the presence of chronic inflammation, these cells often adopt a pro-inflammatory phenotype that reduces their capacity to clear amyloid plaques. However, by inhibiting NLRP3, the researchers found that microglia upregulated genes involved in glutamine metabolism and oxidative phosphorylation, processes essential for maintaining cellular energy and function.

One of the key findings was the identification of Slc1a3, a glutamate transporter, as a critical mediator of these effects. Microglia with reduced NLRP3 activity exhibited increased mitochondrial membrane potential, leading to enhanced phagocytosis of amyloid-β – a function that was lost when Slc1a3 was pharmacologically blocked [1].

Implications for Alzheimer’s treatment strategies

While previous therapeutic efforts have focused primarily on reducing amyloid-β burden, these new findings reinforce the idea that targeting inflammatory pathways could be equally important. The study demonstrated that chronic, rather than short-term, inhibition of NLRP3 was required to induce these metabolic changes [1]. This suggests that sustained modulation of immune function, rather than acute suppression of inflammation, may be necessary to achieve long-term benefits in Alzheimer’s treatment.

“It is known that inhibiting NLRP3 not only reduces neuroinflammation, but also helps microglia clear the harmful amyloid-beta deposits, a process called phagocytosis,” says Dr Róisín McManus, a DZNE research group leader. “The novelty of our findings is that they provide a better understanding of the important role that NLRP3 plays in microglia and we also unravel the mechanism behind why its inhibition is so beneficial [2].”

The authors also found that these mechanisms were conserved across species, as post-mortem brain tissue from Alzheimer’s patients exhibited elevated NLRP3 activity and reduced levels of Slc1a3 [1]. This highlights a potential translational pathway for developing NLRP3-targeted therapies that could be applicable to human disease.

Future directions: moving beyond amyloid-β

The study’s findings align with a growing body of evidence suggesting that Alzheimer’s is not solely an amyloid problem, but a complex disease involving metabolic, immune and neurovascular dysfunction.

“In our studies we have identified previously unknown signaling pathways influenced by NLRP3,” says McManus. “In particular, we found that NLRP3 regulates how microglia use nutrients and how these act on genes that have a major impact on the function of microglia. This is very relevant for their ability to carry out phagocytosis. These findings could help in the development of therapies for dementia. In any case, our research shows that NLRP3 is a promising target for the treatment of Alzheimer’s disease [2].”

The ability to reprogram microglia through metabolic intervention raises new questions about how inflammation could be targeted in neurodegenerative conditions beyond Alzheimer’s, including Parkinson’s disease and frontotemporal dementia.

With several NLRP3 inhibitors currently in clinical trials, this research provides further support for the idea that modulating immune responses could form a multi-targeted approach to neurodegenerative disease treatment. While further studies are needed to assess the long-term safety and efficacy of these interventions, the potential to shift microglial function away from a pro-inflammatory state and towards a protective, homeostatic phenotype represents an important avenue for future research.

By teasing out how neuroinflammation contributes to Alzheimer’s pathology at a metabolic level, this study moves the field one step closer to understanding how immune regulation could shape the future of neurodegenerative disease treatment.